| Índia | Turquia | Áustria | |
| Imunoterapia com Keytruda (Pembolizumab) | de $3,500 | de $3,300 | de $15,000 |
A Bookimed não adiciona taxas extras aos preços de Imunoterapia com Keytruda (Pembolizumab). As tarifas vêm das listas oficiais das clínicas. O pagamento é feito diretamente na clínica na chegada.
A Bookimed está comprometida com sua segurança. Trabalha apenas com instituições que mantêm altos padrões internacionais em Imunoterapia com Keytruda (Pembolizumab) e têm as licenças necessárias para atender pacientes internacionais em todo o mundo.
A Bookimed oferece assistência gratuita de especialistas. Um coordenador médico pessoal apoia antes, durante e após o tratamento, solucionando problemas. Nunca está sozinho em sua jornada de Imunoterapia com Keytruda (Pembolizumab).
O Dr. Ahmer Arif Shaikh é especializado no tratamento do câncer oral e reabilitação funcional no HCG Manavata Cancer Centre.
O Dr. Chaitainya Borde realizou mais de 30.000 exames de PET e tratou mais de 1.000 pacientes com cancro da tiroide no HCG Manavata Cancer Centre.
Mais de 19 anos de experiência em oncologia cirúrgica – O Dr. Nagarkar realizou mais de 50.000 cirurgias de cancro no HCG Manavata Cancer Centre.
O Dr. Girish Badarkhe é especialista no tratamento de cancros do sangue com imunoterapia no HCG Manavata Cancer Centre, oferecendo mais de 13 anos de experiência focada.
Keytruda is an immunotherapy medication that reboots the immune system to identify and kill cancer cells. Unlike chemotherapy, this monoclonal antibody blocks the PD-1 pathway, preventing tumors from hiding and allowing T cells to naturally destroy advanced cancers like melanoma or lung carcinoma.
Bookimed Expert Insight: India has become a global hub for Keytruda due to high-volume expertise at centers like HCG Manavata Cancer Centre, where teams have performed over 50,000 surgeries. While US infusions average $21,500, Indian clinics offer the same immunotherapy starting at $3,500, saving patients up to 77%.
Patient Consensus: Patients emphasize that immunotherapy feels different from chemotherapy because it revs up immunity rather than poisoning cells. many report that monitoring biomarkers like PD-L1 was crucial for predicting their individual success with the drug.
Keytruda is approved in India by the Drug Controller General of India (DCGI). It is cleared for multiple cancer indications including non-small cell lung cancer, melanoma, and triple-negative breast cancer. Treatment is available at JCI-accredited facilities like Artemis Hospitals and Apollo Hospital Indraprastha.
Bookimed Expert Insight: Success with Keytruda in India often depends on doctor experience with immunotherapy protocols. Dr. Shruti Kate at HCG Manavata Cancer Centre specializes specifically in these treatments. Many top Indian clinics now also use IBM Watson AI platforms to verify treatment compatibility.
Patient Consensus: Success depends on confirming drug availability for your specific cancer subtype before traveling. Patients highly value the cost difference but recommend asking about immune-related side effect monitoring plans.